日韩精品欧美专区,国产v综合v亚洲欧美久久,jizz性欧美2,国产精品色婷婷

Ask the Experts: Dengue

Results (37)

Dengue is an infectious disease caused by dengue viruses (DENV) spread among people through the bite of an infected mosquito from the Aedes species (Ae. aegypti or Ae. albopictus). DENV are members of the genus Flavivirus in the family Flaviviridae.

There are four dengue virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4), all of which circulate globally. The four dengue virus serotypes are closely related but can be differentiated on serologic tests. Infection with one serotype generally produces long-lived immunity to that serotype, but only provides short-lived protection against infection with other serotypes. For this reason, a person can be infected with DENV as many as four times in their lifetime.

Symptoms of dengue range from asymptomatic or very mild (75% of cases) to severe disease complicated by shock, bleeding, or severe organ impairment. Fever is the most common symptom of dengue. Other symptoms can include sudden onset of headache, pain behind the eyes, loss of appetite, abdominal pain, nausea, vomiting, muscle aches, bone and joint pain, and flushing of the face. A generalized flat, red rash is often seen within 3–4 days of fever onset. Symptoms typically last 2–7 days, with most people recovering after about a week.

About 1 in 20 patients with dengue progress to severe dengue, typically 24-48 hours after the fever resolves. Severe dengue can become life-threatening within hours, often as a result of hypovolemic shock due to plasma leakage from the vasculature. There is no specific treatment for dengue. With proper supportive care in a hospital or intensive care unit setting, fewer than one in 100 people with severe dengue may die; fatality rates have been reported as high as 13% in the absence of adequate supportive care.

A person’s risk for progression to severe dengue varies based on several factors. Age (over 60), comorbidities (including pregnancy), host genetics, and the infecting virus strain are risk factors for severe dengue. For any individual, the second infection with a different DENV serotype is the most likely to cause severe dengue compared with the first, third, or fourth infections.

CDC has a website with additional details on the clinical presentation of dengue:
https://www.cdc.gov/dengue/hcp/clinical-signs/index.html.

Last reviewed: January 17, 2025

Dengue is common throughout tropical and subtropical regions of the world. About half of the world’s population lives in areas suitable for DENV transmission and the main vector of dengue, the Aedes aegypti mosquito, is difficult to control and continues to expand its geographic range. Each year, up to 400 million people get infected with dengue viruses. Approximately 100 million people get sick from infection, and about 40,000 die from severe dengue.

Dengue is endemic in the United States territories and freely associated states of Puerto Rico, American Samoa, the U.S. Virgin Islands, the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau. CDC classifies an area as endemic for dengue if the area has frequent or continuous dengue transmission, with evidence of more than 10 dengue cases in at least three of the previous 10 years. Dengue epidemics occur in a cyclical pattern every 3–7 years, with all four DENV serotypes reported in the Pacific Islands and the Caribbean. Limited surveillance data are available from the Federated States of Micronesia, the Republic of Marshall Islands, and the Republic of Palau.

Dengue can cause outbreaks with high numbers of cases in some years. In 2021, only 435 cases were reported in US territories, and 63 cases were reported in U.S. states. In 2024, over 12 million cases of dengue were reported in the Western Hemisphere, with U.S. states and territories reporting 9,391 cases. Of these cases, 3,224 cases were travel-associated and 6,076 were locally acquired in Puerto Rico (5,881) and the U.S. Virgin Island (185).

About 90% of the population at risk for dengue in US territories live in Puerto Rico. From 2010-20, approximately 95% of locally acquired dengue cases in the US occurred in Puerto Rico (29,779 cases), with the most cases and hospitalizations in Puerto Rico occurring among adolescents age 10 through 19 years (11,000 cases leading to 4,000 hospitalizations). Small convenience studies of children ages 9 through 16 conducted during vaccine trials estimated that 50% to 56% of children in this age group showed serologic evidence of past DENV infection. Dengue is not endemic in the continental United States or Hawaii at this time.

Last reviewed: January 17, 2025

Multiple complex mechanisms likely contribute to increased disease severity during a second DENV infection. The published ACIP recommendation provides a detailed description of these mechanisms at www.cdc.gov/mmwr/volumes/70/rr/pdfs/rr7006a1-H.pdf. In addition, CDC has developed simple illustrations and descriptions to explain this phenomenon at https://www.cdc.gov/dengue/hcp/vaccine/eligibility.html.

Last reviewed: January 17, 2025

Dengvaxia (Sanofi) is a live-attenuated, chimeric tetravalent dengue vaccine built on a yellow fever 17D backbone. It is designed to protect against all four DENV serotypes. It was licensed by the FDA in May 2019 for children and adolescents age 9 through 16 years with a confirmed history of previous dengue infection. FDA lowered the youngest age for licensed use from 9 years to 6 years in 2023; however, CDC’s recommendations to begin routine vaccination of children with serologic evidence of prior dengue infection at age 9 years remains unchanged. The recommendation for vaccination is restricted to people age 9 through 16 years with confirmed previous DENV infection because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination.

In 2024, Sanofi announced plans to discontinue production of Dengvaxia in the third quarter of 2026 due to low global demand. Other dengue vaccines are in late stages of development; however, there are no other licensed dengue vaccines available in the United States.

Last reviewed: January 17, 2025

Vaccine efficacy (VE) during clinical trials in multiple countries ranged from 76% to 82%. VE varied by serotype and was highest for DENV-4 (89% point estimate) and lowest for DENV-1 and DENV-2 (67% point estimate). Among study participants ages 9 through 16 years who developed protective antibodies, the vaccine reduced their risk of hospitalization with dengue by 79% and reduced their risk of severe dengue by 84% over the 5-year follow-up period after vaccination. Studies are ongoing to determine how long protection from hospitalization or severe disease may last, but current evidence show protection lasting at least 6 years after the last dose of vaccine.

Last reviewed: January 17, 2025

No, Dengvaxia does not protect the recipient against yellow fever.

Last reviewed: January 17, 2025

In June 2021, ACIP voted to recommend Dengvaxia for routine use in children age 9 through 16 years with laboratory-confirmed previous dengue virus infection and living in areas where CDC has classified dengue as endemic. The recommendation is only for persons with confirmed previous DENV infection because Dengvaxia is associated with an increased risk for severe dengue in those who experience their first natural infection (i.e., primary infection) after vaccination.

The vaccine is not approved for use in U.S. travelers who are visiting but not living in an area where dengue is common.

The most current ACIP recommendations for Dengvaxia are available at www.cdc.gov/mmwr/volumes/70/rr/pdfs/rr7006a1-H.pdf.

CDC has developed a pre-vaccination checklist for evaluating whether a child should receive Dengvaxia: www.cdc.gov/dengue/resources/DVBD_FS_Vaccination_Checklist-508.pdf.

Last reviewed: January 17, 2025

Yes. Dengvaxia is included in the VFC program. The most current VFC resolution is available at www.cdc.gov/vaccines-for-children/about/index.html.

The cost of the pre-vaccination screening test will be covered by Medicaid for those who are eligible.

Last reviewed: January 17, 2025

Children with confirmation of previous DENV infection need three doses of Dengvaxia, given 6 months apart, for complete protection (0, 6 months, 12 months). Recipients achieve significant protection following dose 1.

Last reviewed: January 17, 2025

No, it is not. It is only recommended for children and teens ages 9 through 16 who reside in dengue endemic areas.

Last reviewed: January 17, 2025

No. Dengvaxia is FDA-licensed only for children and teens ages 6 years through 16 years.

Last reviewed: January 17, 2025

CDC does not recommend Dengvaxia for non-residents of areas where dengue is endemic. If the child spends regular extended periods in Puerto Rico to point that they are considered a part-time resident, the family should consult with the child’s health care provider in Puerto Rico for assessment.

Last reviewed: January 17, 2025

Dengvaxia is a live-attenuated vaccine. Live virus vaccines are generally not recommended during pregnancy; however, people infected with DENV during pregnancy are at increased risk of severe dengue. Perinatal transmission may occur with peripartum maternal infection increasing the risk of symptomatic illness in the newborn. The ACIP recommendations classify pregnancy as a precaution to vaccination with Dengvaxia.

Pregnant people were not explicitly enrolled and studied in the Dengvaxia vaccine trials. A minimal number of pregnant women in the trial inadvertently received Dengvaxia. There was no increased frequency of adverse pregnancy outcomes (e.g., spontaneous abortion, intrauterine death, stillbirth) noted compared to the control group. However, due to the small sample size, no conclusions can be made on the possible effect of Dengvaxia on pregnancy.

Providers should consider the pregnant person’s risk of DENV infection and its complications when deciding whether or not to recommend Dengvaxia during pregnancy or to defer until after pregnancy.

Last reviewed: January 17, 2025

CDC recommends that Dengvaxia should be used with precaution in breastfeeding individuals. There are no data in humans to evaluate the safety of Dengvaxia in infants who are breastfed. Providers and breastfeeding parents should weigh the benefits of breastfeeding and the risk of DENV infection in the mother and the infant.

Last reviewed: January 17, 2025

Dengvaxia is a live-attenuated vaccine and is contraindicated in children with severe immunodeficiency or immunosuppression due to underlying disease or therapy, including children with symptomatic HIV infection or CD4+ T-lymphocyte count below 200 per cubic milliliter.

The ACIP recommendations state that Dengvaxia may be used with precaution in people with HIV infection who do not meet the criteria for contraindication, based on an assessment of the person’s risk of vaccination against the risk of dengue and its complications.

Last reviewed: January 17, 2025

Administration of Dengvaxia to a person who has never been infected with DENV may result in an increased risk of hospitalization and severe dengue illness if they are infected with natural (wild type) DENV for the first time after vaccination. Multiple complex mechanisms likely contribute to increased disease severity during a second DENV infection. The published ACIP recommendation provides a detailed description of these mechanisms at www.cdc.gov/mmwr/volumes/70/rr/pdfs/rr7006a1-H.pdf. In addition, CDC has developed simple illustrations and descriptions to explain this phenomenon at https://www.cdc.gov/dengue/hcp/vaccine/eligibility.html.

In a person who has never been infected with DENV, vaccination with Dengvaxia may “stand in” (immunologically) for the first natural infection, resulting in an increased risk of severe dengue in response to the first natural infection because the immune system responds as if that infection were the “second” infection.

Last reviewed: January 17, 2025

CDC has established strict accuracy criteria for the laboratory tests considered acceptable proof of past DENV infection before vaccination of a child.

No test is perfectly accurate: wrong results lead to different types of risk. A false negative test result means a child who is at increased risk of severe dengue would not be protected by vaccination. A false positive test means a child who was not at high risk of severe dengue would be vaccinated, potentially increasing the child’s risk of severe dengue if the child experiences a subsequent DENV infection.

All dengue IgG tests for pre-vaccination screening must have a minimum specificity of at least 98% to minimize the chance of misclassifying a person who should have a true negative test result as positive. This high specificity minimizes the risk of vaccinating a person who should not be vaccinated.

Pre-vaccination screening tests must also have a sensitivity of at least 75% to accurately identify a high proportion of children and adolescents with past dengue virus infections who can benefit from vaccination.

Acceptable laboratory confirmation of previous dengue virus infection can be obtained by:

  • Evidence of prior acute dengue virus infection with
    • Positive dengue RT-PCR test result, or
    • Positive dengue NS1 antigen test result
  • OR, positive results on BOTH of the following anti-dengue virus IgG antibody tests in a two-step testing algorithm:
    • EUROIMMUN Anti-Dengue Virus NS1 Type 1-4 ELISA (IgG) and
    • CTK BIOTECH OnSite Dengue IgG Rapid Test

Visit www.cdc.gov/dengue/vaccine/hcp/testing.html. for additional information about laboratory testing requirements for vaccination with Dengvaxia. As additional tests are evaluated and approved as acceptable, information will be updated by CDC.

Vaccinators are encouraged to use the CDC prevaccination checklist to evaluate patient eligibility: www.cdc.gov/dengue/resources/DVBD_FS_Vaccination_Checklist-508.pdf.

Last reviewed: January 17, 2025

No. IgM tests for acute DENV infection are not sufficiently accurate to be acceptable evidence for the purposes of vaccination. These tests may be falsely positive as a result of other flavivirus infections that may cause similar symptoms (such as Zika).

Acceptable evidence of acute infection with DENV is either a positive dengue RT-PCR test result, or a positive dengue NS1 antigen test result.

Visit CDC’s website on laboratory testing requirements for vaccination with Dengvaxia for additional information: www.cdc.gov/dengue/vaccine/hcp/testing.html.

Last reviewed: January 17, 2025

Patients with a negative test should be re-tested every 1 or 2 years (while remaining between the ages of 9 through 16 years) or based on the clinical judgment of the health care provider.

CDC recommends that children and adolescents who are acutely ill with dengue virus infection should wait at least 6 months after the date dengue virus infection is confirmed to begin the vaccine series. https://www.cdc.gov/dengue/hcp/vaccine/schedule-dosing.html.

Last reviewed: January 17, 2025

ACIP recommends a 3-dose Dengvaxia vaccine schedule, with doses administered at 0, 6 months, and 12 months.

Last reviewed: January 17, 2025

The recommended interval is 6 calendar months between each dose, and the minimum interval is 5 calendar months between each dose. In accordance with CDC’s general best practice guidelines, a dose administered up to 4 days before the minimum interval may be counted as valid. If a dose is given too early, the recommendation is to repeat the dose at the minimum interval of 5 months.

Last reviewed: January 17, 2025

Dengvaxia is administered as a 3-dose series, spaced 6 months apart (0, 6, and 12 months). Each dose is 0.5 mL in volume, administered subcutaneously. The vaccine comes in powder form (lyophilized) in single dose vials. Each lyophilized vaccine vial should be mixed with the supplied diluent, a vial of saline diluent (0.4% NaCl). To reconstitute Dengvaxia, withdraw 0.6 ml from the diluent vial and inject it into the lyophilized vaccine vial. Swirl the vial gently. After reconstitution, the suspension is colorless and may develop trace amounts of white to translucent particles.

After reconstitution, 0.5 mL of Dengvaxia should be withdrawn and immediately administered subcutaneously. If not used immediately, the reconstituted vaccine should be refrigerated at 36°F–46°F (2°C–8°C) and used within 30 minutes. Do not use the vaccine more than 30 minutes after reconstitution.

Dengvaxia is for subcutaneous use only. Dengvaxia should not be administered by intramuscular injection; however, if administered intramuscularly in error, the dose does not need to be repeated.

CDC has a web page dedicated to the storage and reconstitution of Dengvaxia: https://www.cdc.gov/dengue/hcp/vaccine/storage-handling.html.

Last reviewed: January 17, 2025

No, the dose should not be repeated. The Clinical Implications of Nonstandard Vaccination Practices subsection of the Vaccine Administration section of CDC’s General Best Practices for Immunization explains that the immune response to vaccines recommended to be administered by the subcutaneous route is unlikely to be affected if the vaccines are inadvertently administered by the intramuscular route. For this reason, repeating doses of vaccine administered by the intramuscular route when recommended by the subcutaneous route is not necessary. See this subsection here: www.cdc.gov/vaccines/hcp/imz-best-practices/vaccine-administration.html#cdc_report_pub_study_section_6-clinical-implications-of-nonstandard-vaccination-practices.

Last reviewed: January 17, 2025

Yes, Dengvaxia may be given at the same visit with any live or non-live vaccines that are also indicated for the patient.

If Dengvaxia is not administered on the same day as another live vaccine, the two vaccines should be separated by at least 4 weeks to minimize the potential risk of interference.

Last reviewed: January 17, 2025

You should continue where the patient left off and complete the series. You never have to restart the series.

Last reviewed: January 17, 2025

Yes. You must initiate the series while the recipient is age 16 years, but you may complete the series even if the recipient turns 17 before the series is completed.

Last reviewed: January 17, 2025

The parent/caregiver should be notified immediately, warned of the possible increased risk for hospitalization and severe dengue if the person develops a subsequent natural dengue infection, and the need to seek immediate medical attention if warning signs of severe dengue develop.

Clinic staff should review the incident and ensure that staff members responsible for vaccination have had sufficient training and protocols are in place to prevent such errors.

The use of tools, such as the CDC prevaccination checklist, helps prevent such errors: (www.cdc.gov/dengue/resources/DVBD_FS_Vaccination_Checklist-508.pdf).

Last reviewed: January 17, 2025

Children and adolescents who have been diagnosed with acute dengue should wait at least 6 months after the date the dengue illness is confirmed to begin the vaccine series.

Last reviewed: January 17, 2025

Dengvaxia is contraindicated for people with a history of immediate hypersensitivity to any vaccine component or a previous dose of this vaccine. A complete list of vaccine components is available in the package insert at www.fda.gov/media/124379/download.

Dengvaxia is a live-attenuated vaccine and also is contraindicated in children with severe immunodeficiency or immunosuppression due to underlying disease or therapy, including children with symptomatic HIV infection or CD4+ T-lymphocyte count of less than 200 per cubic milliliter.

Lack of laboratory evidence of previous dengue infection is also a contraindication to Dengvaxia. www.cdc.gov/vaccines/vpd/dengue/hcp/recommendations.html.

Last reviewed: January 17, 2025

A precaution to Dengvaxia is a moderate or severe acute illness with or without fever. Vaccination should be deferred until the condition improves.

ACIP recommends that Dengvaxia may be used with precaution in certain special populations for whom the risks and benefits of vaccination to prevent DENV infection must be evaluated but for whom limited safety data are available. These groups include pregnant people, breastfeeding people, and people with HIV that is controlled and does not meet the criteria for a contraindication.

Last reviewed: January 17, 2025

Administration of Dengvaxia to a person who has never been infected with DENV may result in an increased risk of hospitalization and severe dengue illness if they are infected with natural (wild type) DENV for the first time after vaccination.

Multiple complex mechanisms likely contribute to increased disease severity during a second DENV infection. The published ACIP recommendation provides a detailed description of these mechanisms at www.cdc.gov/mmwr/volumes/70/rr/pdfs/rr7006a1-H.pdf. In addition, CDC has developed simple illustrations and descriptions to explain this phenomenon at https://www.cdc.gov/dengue/hcp/vaccine/eligibility.html.

In a person who has never been infected with DENV, vaccination with Dengvaxia may “stand in” (immunologically) for the first natural infection, resulting in an increased risk of severe dengue in response to the first natural infection because the immune system responds as if that infection were the “second” infection.

Last reviewed: January 17, 2025

The most frequently reported side effects among vaccine recipients in the clinical trials were headache (40%), injection site pain (32%), malaise (25%), fatigue (25%), and muscle aches (29%).

As with any vaccine, healthcare providers should report any clinically significant adverse event to the Vaccine Adverse Events Reporting System (VAERS) at www.vaers.hhs.gov. even if a causal relation to vaccination is unknown or not certain.

Last reviewed: January 17, 2025

Syncope (fainting) can occur before or after vaccination because of a vasovagal response to needles. Children should be seated or lying down during vaccination. Consider observing patients (with the patient seated or lying) for 15 minutes after vaccination to decrease the risk for injury should the patient faint. If syncope develops, the patient should be observed until the symptoms resolve. Immunize.org has simple, 1-page information sheets for patients (www.immunize.org/wp-content/uploads/catg.d/p4260a.pdf) and for healthcare professionals (www.immunize.org/wp-content/uploads/catg.d/p4260.pdf) concerning syncope and vaccination.

Last reviewed: January 17, 2025

Yes. The current VIS for Dengvaxia is available in both English and Spanish at www.immunize.org/vis/vis_dengue.asp.

Last reviewed: January 17, 2025

No, Dengvaxia is not included in the VICP at this time.

For additional information, visit www.hrsa.gov/vaccine-compensation/faq.

Last reviewed: January 17, 2025

No. You should only use the (0.4% NaCl) diluent provided with the Dengvaxia vaccine vial. Contact your immunization program or the manufacturer for additional guidance.

Last reviewed: January 17, 2025

Store both the vaccine antigen and the diluent in a refrigerator at 36°F–46°F (2°C–8°C). Do not freeze. Protect from light. After reconstitution, administer Dengvaxia immediately or store refrigerated at 36°F–46°F (2°C–8°C) and use within 30 minutes.

Do not use the vaccine if it has been reconstituted for over 30 minutes. Contact your public health immunization program or the manufacturer for advice if vaccination occurs using vaccine that has been reconstituted more than 30 minutes, or in the event of other storage or handling errors.

The manufacturer package insert contains additional information and can be found at www.fda.gov/media/124379/download.

For complete information on vaccine storage and handling best practices and recommendations, please refer to CDC’s Vaccine Storage and Handling Toolkit at www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf.

Last reviewed: January 17, 2025

This page was updated on .

日韩精品欧美专区,国产v综合v亚洲欧美久久,jizz性欧美2,国产精品色婷婷
成人黄页毛片网站| 亚洲成国产人片在线观看| 国产成人自拍网| 亚洲v日本v欧美v久久精品| 色素色在线综合| 狠狠久久亚洲欧美| 久久电影网站中文字幕| 国产久卡久卡久卡久卡视频精品| 日韩亚洲欧美一区| 国产91精品一区二区麻豆网站| 亚洲不卡一区二区三区| 欧美va在线播放| 欧美一区午夜视频在线观看| 亚洲欧洲在线观看av| 99精品国产一区二区三区不卡| 亚洲成人av一区二区| 国产一区福利在线| 欧美一区二区免费视频| 国产精品美女久久久久久久久久久| 国产色综合久久| 精品久久久三级丝袜| 毛片基地黄久久久久久天堂| 毛片av一区二区三区| 国产亚洲欧美在线| 成人三级在线视频| 欧美色综合影院| 91精品国产91热久久久做人人| 成人黄色在线看| 蜜臀av性久久久久蜜臀aⅴ| 亚洲欧美电影一区二区| 在线观看亚洲精品视频| 亚洲精品中文在线影院| 久久婷婷国产综合国色天香| 精品一区二区精品| 日本精品一区二区三区高清| 日本va欧美va欧美va精品| 91视频一区二区三区| 国产精品二三区| 精品成人一区二区三区| 97久久精品人人做人人爽| 国产成人午夜99999| 色噜噜久久综合| 亚洲一区二区三区四区在线免费观看| 日韩欧美精品三级| 欧美色图在线观看| 久久综合狠狠综合久久综合88| 久久国产综合精品| 91麻豆精品91久久久久同性| 精品国产自在久精品国产| 国产精品久久夜| 国产一区视频在线看| 菠萝蜜视频在线观看一区| 亚洲成人一区在线| 精品少妇一区二区| 亚洲欧洲www| 综合电影一区二区三区| 一区二区三区国产精品| 日韩毛片高清在线播放| 亚洲精品乱码久久久久久久久| ●精品国产综合乱码久久久久| 亚洲欧美中日韩| 福利电影一区二区| 三级欧美在线一区| 视频一区欧美日韩| 亚洲色图丝袜美腿| 久久久久成人黄色影片| 成人激情动漫在线观看| 色综合激情五月| 国产伦理精品不卡| 亚洲一区二区高清| 亚洲蜜桃精久久久久久久| 国产无人区一区二区三区| 欧美最新大片在线看| 精品久久久久久久久久久久久久久| 亚洲国产精品高清| 一区二区三区在线不卡| 成人动漫在线一区| 日韩电影在线免费| 国产福利一区二区三区在线视频| 懂色av一区二区三区免费看| 亚洲高清免费一级二级三级| 国产女同互慰高潮91漫画| 91蜜桃婷婷狠狠久久综合9色| 一区二区在线观看视频在线观看| 中文字幕精品综合| 色综合中文字幕国产| 欧美成人一区二区三区在线观看| 亚洲成年人网站在线观看| 亚洲欧美电影一区二区| 国产精品网友自拍| 国产精品无人区| 一区二区三区四区中文字幕| 色94色欧美sute亚洲13| 日韩电影网1区2区| 日韩av一级片| 日本成人超碰在线观看| 99re视频这里只有精品| 色综合一区二区三区| 色成人在线视频| 精品一区二区三区视频在线观看| 日韩午夜在线观看| 一区二区国产视频| 欧美日韩综合在线| 久久久久九九视频| 欧美日韩高清不卡| 亚洲一级二级在线| 香蕉成人啪国产精品视频综合网| 亚洲成av人片一区二区梦乃| 91电影在线观看| 欧美亚洲国产怡红院影院| 国产视频一区不卡| 91精品国产综合久久福利软件| 欧美日韩精品免费观看视频| 99vv1com这只有精品| 国产一区二区三区精品视频| 国产一级精品在线| 中文字幕欧美一区| 国产日产欧美一区| 一区二区国产视频| 亚洲欧美国产毛片在线| 成年人国产精品| 另类小说视频一区二区| 日本一区二区电影| 成人国产视频在线观看| 欧美精品一区二| 伊人性伊人情综合网| 91美女蜜桃在线| 看片的网站亚洲| 91成人看片片| 成人网在线播放| 欧美理论电影在线| 久草热8精品视频在线观看| 国产在线精品一区二区三区不卡| 日本伦理一区二区| 亚洲精品一线二线三线无人区| 亚洲成人福利片| 国产精品网曝门| 日韩一区有码在线| 午夜久久久久久久久| 国产丝袜美腿一区二区三区| 寂寞少妇一区二区三区| 欧美日韩专区在线| 亚洲黄色小说网站| 另类小说综合欧美亚洲| 欧美va亚洲va在线观看蝴蝶网| 久久尤物电影视频在线观看| 精品精品国产高清一毛片一天堂| 国产精品国产精品国产专区不片| 日韩精品一级中文字幕精品视频免费观看| 欧美理论在线播放| 色天天综合久久久久综合片| 日本久久一区二区三区| 亚洲国产色一区| 亚洲免费观看在线视频| 亚洲狠狠丁香婷婷综合久久久| 亚洲一线二线三线久久久| 国产午夜亚洲精品不卡| 久久久国产一区二区三区四区小说| 一区二区三区中文字幕| 欧美激情一区二区三区四区| 久久精品人人爽人人爽| 欧美一区二区三区四区在线观看| 国产成人av影院| 亚洲欧美乱综合| 午夜日韩在线观看| 4438亚洲最大| 欧美精品粉嫩高潮一区二区| 国产一区二区三区在线观看免费| 久久久午夜精品理论片中文字幕| 亚洲国产欧美一区二区三区丁香婷| 成人性生交大片免费看视频在线| 国产一级精品在线| 欧美日韩成人综合在线一区二区| 正在播放亚洲一区| 亚洲一区二区三区四区不卡| 粉嫩绯色av一区二区在线观看| 91国内精品野花午夜精品| 亚洲成av人片在线观看无码| 石原莉奈一区二区三区在线观看| 欧美不卡一区二区三区四区| 国产精品久久三| 精品久久一区二区三区| 精品日韩一区二区三区免费视频| 成人午夜电影久久影院| 国产91精品入口| 亚洲图片欧美激情| 亚洲一区二区三区四区五区黄| 国产a视频精品免费观看| 日韩欧美不卡一区| 免费成人美女在线观看.| 成人黄色一级视频| 亚洲精品国产精品乱码不99| 亚洲免费观看视频| 亚洲女人****多毛耸耸8| 国产精品久久久久四虎| 日韩一级大片在线| 一本一道久久a久久精品综合蜜臀| 久久精品欧美一区二区三区不卡| 天天影视涩香欲综合网| 91影院在线免费观看|